Hospital Universitario Donostia, San Sebastián, Spain.
Hospital Universitario Donostia, San Sebastián, Spain; BIODONOSTIA Health Research Institute, San Sebastián, Spain.
Eur J Obstet Gynecol Reprod Biol. 2021 Jun;261:59-64. doi: 10.1016/j.ejogrb.2021.04.015. Epub 2021 Apr 15.
The aim of this study was to describe our latest results using dual cervical and fundal indocyanine green injection for detection of sentinel lymph node (SLN) in endometrial cancer.
A prospective observational study was conducted between 26 June 2014 and 31 December 2019 with 278 patients that underwent laparoscopic surgery for endometrial cancer at our institution. In all cases, we performed SLN biopsy with dual cervical and fundal indocyanine green injection. All SLNs were processed with an ultrastaging technique. A total of 128 patients also underwent total pelvic and paraaortic lymphadenectomy.
The detection rates were as follows: 93.5 % (260/278) overall for SLNs; 90.7 % (252/278) overall for pelvic SLNs; 68.0 % (189/278) for bilateral SLNs; 66.9 % (186/278) for paraaortic SLNs, and 2.9 % (8/278) for isolated paraaortic SLNs. We found macroscopic lymph node metastasis in 26 patients (10.0 %) and microdisease in lymph nodes in another 48 patients, raising the overall rate of lymph node involvement to 16.2 %. There was one false negative (negative SLN biopsy but positive lymphadenectomy). Applying the SLN algorithm, the sensitivity of detection was 97.9 % (95 % CI 89.1-99.6), specificity 100 % (95 % CI 98.2-100), negative predictive value 99.5 % (95 % CI 97.4-99.9), and positive predictive value 100 % (95 % CI 92.4-100).
Dual sentinel node injection is a feasible technique that achieves adequate detection rates. Additionally, this technique allows a high rate of aortic detection, identifying a non-negligible percentage of isolated aortic metastases. Aortic metastases in endometrial cancer are possible and we should not give up actively looking for them.
本研究旨在描述我们使用双宫颈和底池吲哚菁绿注射检测子宫内膜癌前哨淋巴结 (SLN) 的最新结果。
这是一项在 2014 年 6 月 26 日至 2019 年 12 月 31 日期间进行的前瞻性观察性研究,共有 278 名在我院接受腹腔镜手术治疗子宫内膜癌的患者参与。在所有情况下,我们均使用双宫颈和底池吲哚菁绿注射进行 SLN 活检。所有 SLN 均采用超微分期技术进行处理。共有 128 名患者还接受了全盆腔和腹主动脉旁淋巴结清扫术。
SLN 的检出率如下:总检出率为 93.5%(260/278);盆腔 SLN 总检出率为 90.7%(252/278);双侧 SLN 总检出率为 68.0%(189/278);腹主动脉旁 SLN 总检出率为 66.9%(186/278);孤立性腹主动脉旁 SLN 检出率为 2.9%(8/278)。我们发现 26 名患者(10.0%)有肉眼可见的淋巴结转移,另有 48 名患者的淋巴结有微转移,从而使淋巴结受累的总体发生率上升至 16.2%。有 1 例假阴性(SLN 活检阴性但淋巴结清扫阳性)。应用 SLN 算法,检测的灵敏度为 97.9%(95%CI89.1-99.6),特异性为 100%(95%CI98.2-100),阴性预测值为 99.5%(95%CI97.4-99.9),阳性预测值为 100%(95%CI92.4-100)。
双前哨淋巴结注射是一种可行的技术,可达到足够的检出率。此外,该技术还能提高主动脉检出率,发现非小比例的孤立性主动脉转移。子宫内膜癌中存在主动脉转移的可能性,我们不应主动放弃寻找它们。